Skip to content

Study · Randomized controlled trial · n = 1,085 · 2005

5 results

The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis.

Genant HK, Halse J, Briney WG, Xie L, Glass EV, Krege JH

Current medical research and opinion1 Jul 2005Cited by 46 (Europe PMC)

PMID16004669 (opens in a new tab)DOI10.1185/030079905x49671 (opens in a new tab)PepBankPUB-16004669
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, teriparatide reduced the relative risk of moderate or severe back pain risk by 31% versus placebo.

    In plain wordsIn women with osteoporosis, teriparatide reduced moderate or severe back pain versus placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseModerate or severe back pain
    Study

    n = 1,085

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Pain · Musculoskeletal
    Studied dose
    20 microg · median 19 monthsAs given in this study (human).

    Measurements

    Relative risk reduction
    31%
    moderate or severe back pain, teriparatide versus placebo
    Incidence
    16.5%
    moderate or severe back pain, placebo group
    Incidence
    11.5%
    moderate or severe back pain, teriparatide 20 microg group

    Source sentences

    Summary
    Women randomized to teriparatide 20 microg had a 31% reduced relative risk of moderate or severe back pain (16.5% vs. 11.5%, P = 0.016) and a 57% reduced risk of severe back pain (5.2% vs. 2.2%, P = 0.011).
    2 context sentences
    Summary · context
    The risk of developing back pain was assessed following treatment with teriparatide [rh(PTH 1-34)] in postmenopausal women with osteoporosis.
    Summary · context
    postmenopausal women with prevalent vertebral fractures were administered teriparatide 20 microg (n = 541) or placebo (n = 544) for a median of 19 months.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, teriparatide reduced the relative risk of severe back pain risk by 57% versus placebo.

    In plain wordsIn women with osteoporosis, teriparatide reduced severe back pain versus placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseSevere back pain
    Study

    n = 1,085

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Pain · Musculoskeletal
    Studied dose
    20 microg · median 19 monthsAs given in this study (human).

    Measurements

    Relative risk reduction
    57%
    severe back pain, teriparatide versus placebo
    Incidence
    5.2%
    severe back pain, placebo group
    Incidence
    2.2%
    severe back pain, teriparatide 20 microg group

    Source sentences

    Summary
    Women randomized to teriparatide 20 microg had a 31% reduced relative risk of moderate or severe back pain (16.5% vs. 11.5%, P = 0.016) and a 57% reduced risk of severe back pain (5.2% vs. 2.2%, P = 0.011).
    2 context sentences
    Summary · context
    The risk of developing back pain was assessed following treatment with teriparatide [rh(PTH 1-34)] in postmenopausal women with osteoporosis.
    Summary · context
    postmenopausal women with prevalent vertebral fractures were administered teriparatide 20 microg (n = 541) or placebo (n = 544) for a median of 19 months.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, teriparatide reduced the relative risk of back pain risk associated with one or more new vertebral fractures by 83% versus placebo.

    In plain wordsIn women with osteoporosis, teriparatide reduced back pain associated with new vertebral fractures versus placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseBack pain with at least one new vertebral fracture
    Study

    n = 1,085

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Pain · Musculoskeletal
    Studied dose
    20 microg · median 19 monthsAs given in this study (human).

    Measurements

    Relative risk reduction
    83%
    back pain with one or more new vertebral fractures, teriparatide versus placebo
    Incidence
    6.5%
    back pain with one or more new vertebral fractures, placebo group
    Incidence
    1.1%
    back pain with one or more new vertebral fractures, teriparatide 20 microg group

    Source sentences

    Summary
    Compared with placebo, teriparatide-treated patients experienced reduced relative risk of developing back pain associated with findings of: one or more new vertebral fractures by 83% (6.5% vs. 1.1%, P < 0.001),
    2 context sentences
    Summary · context
    The risk of developing back pain was assessed following treatment with teriparatide [rh(PTH 1-34)] in postmenopausal women with osteoporosis.
    Summary · context
    postmenopausal women with prevalent vertebral fractures were administered teriparatide 20 microg (n = 541) or placebo (n = 544) for a median of 19 months.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, teriparatide reduced the relative risk of back pain risk associated with two or more new vertebral fractures by 91% versus placebo.

    In plain wordsIn women with osteoporosis, teriparatide reduced back pain associated with multiple new vertebral fractures versus placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseBack pain with at least two new vertebral fractures
    Study

    n = 1,085

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Pain · Musculoskeletal
    Studied dose
    20 microg · median 19 monthsAs given in this study (human).

    Measurements

    Relative risk reduction
    91%
    back pain with two or more new vertebral fractures, teriparatide versus placebo
    Incidence
    2.5%
    back pain with two or more new vertebral fractures, placebo group
    Incidence
    0.2%
    back pain with two or more new vertebral fractures, teriparatide 20 microg group

    Source sentences

    Summary
    two or more new vertebral fractures by 91% (2.5% vs. 0.20%, P = 0.004),
    3 context sentences
    Summary · context
    Compared with placebo, teriparatide-treated patients experienced reduced relative risk of developing back pain associated with findings of:
    Summary · context
    The risk of developing back pain was assessed following treatment with teriparatide [rh(PTH 1-34)] in postmenopausal women with osteoporosis.
    Summary · context
    postmenopausal women with prevalent vertebral fractures were administered teriparatide 20 microg (n = 541) or placebo (n = 544) for a median of 19 months.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, teriparatide reduced the relative risk of back pain risk associated with one or more new moderate or severe vertebral fractures by 100% versus placebo.

    In plain wordsIn women with osteoporosis, teriparatide reduced back pain associated with new moderate or severe vertebral fractures versus placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseBack pain with new moderate or severe vertebral fractures
    Study

    n = 1,085

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Pain · Musculoskeletal
    Studied dose
    20 microg · median 19 monthsAs given in this study (human).

    Measurements

    Relative risk reduction
    100%
    back pain with one or more new moderate or severe vertebral fractures, teriparatide versus placebo
    Incidence
    5.1%
    back pain with one or more new moderate or severe vertebral fractures, placebo group
    Incidence
    0%
    back pain with one or more new moderate or severe vertebral fractures, teriparatide 20 microg group

    Source sentences

    Summary
    one or more new moderate or severe vertebral fractures by 100% (5.1% vs. 0.0%, P < 0.001).
    3 context sentences
    Summary · context
    Compared with placebo, teriparatide-treated patients experienced reduced relative risk of developing back pain associated with findings of:
    Summary · context
    The risk of developing back pain was assessed following treatment with teriparatide [rh(PTH 1-34)] in postmenopausal women with osteoporosis.
    Summary · context
    postmenopausal women with prevalent vertebral fractures were administered teriparatide 20 microg (n = 541) or placebo (n = 544) for a median of 19 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.